--- title: "Zosurabalpin (RG6006): The First-in-Class Macrocyclic Peptide Antibiotic Taking on a Critical Superbug (June 27, 2026) | PepTracker Pro Blog" description: "Zosurabalpin (RG6006) is the first antibiotic of a brand-new structural class in decades — a tethered macrocyclic peptide that kills carbapenem-resistant Acinetobacter baumannii by jamming the bacterium's LPS transporter. Here's how it works and why its move into Phase 3 matters." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "Article", "headline": "Zosurabalpin (RG6006): The First-in-Class Macrocyclic Peptide Antibiotic Taking on a Critical Superbug (June 27, 2026)", "description": "Zosurabalpin (RG6006) is the first antibiotic of a brand-new structural class in decades — a tethered macrocyclic peptide that kills carbapenem-resistant Acinetobacter baumannii by jamming the bacterium's LPS transporter. Here's how it works and why its move into Phase 3 matters.", "datePublished": "2026-06-27", "dateModified": "2026-06-27", "author": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "publisher": { "@type": "Organization", "name": "PepTracker Pro", "logo": { "@type": "ImageObject", "url": "https://peptrackerpro.com/favicon.png" } }, "mainEntityOfPage": { "@type": "WebPage", "@id": "https://peptrackerpro.com/blog/zosurabalpin-rg6006-macrocyclic-peptide-antibiotic-crab-acinetobacter-lps-transport-june-27-2026" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Blog", "item": "https://peptrackerpro.com/blog" }, { "@type": "ListItem", "position": 3, "name": "Zosurabalpin (RG6006): The First-in-Class Macrocyclic Peptide Antibiotic Taking on a Critical Superbug (June 27, 2026)", "item": "https://peptrackerpro.com/blog/zosurabalpin-rg6006-macrocyclic-peptide-antibiotic-crab-acinetobacter-lps-transport-june-27-2026" } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Blog](/blog)/ Zosurabalpin (RG6006): The First-in-Class Macrocyclic Peptide Antibiotic Taking on a Critical Superbug (June 27, 2026) Research & Compounds Research & Compounds # Zosurabalpin (RG6006): The First-in-Class Macrocyclic Peptide Antibiotic Taking on a Critical Superbug (June 27, 2026) PepTracker Pro Research Team June 27, 2026 9 min read ## Table of Contents - [A peptide that fights bacteria, not body fat](#section-0) - [How it works — jamming the bacterium's LPS conveyor belt](#section-1) - [Why carbapenem-resistant Acinetobacter is such a problem](#section-2) - [The evidence so far](#section-3) - [The 2026 news — moving into Phase 3](#section-4) - [Why it matters in 2026](#section-5) ## A peptide that fights bacteria, not body fat Most of the peptides getting attention right now work on metabolism, growth hormone or healing. Zosurabalpin is a different animal entirely. It is an investigational antibiotic — a tethered macrocyclic peptide (MCP) built from a ring-shaped peptide scaffold linked to a small-molecule warhead — and it represents the first genuinely new structural and mechanistic class of antibiotic to reach late-stage development in decades. Developed by Roche and discovered by screening roughly 45,000 compounds, it was designed for a single, very dangerous job: killing carbapenem-resistant Acinetobacter baumannii (CRAB), a hospital superbug the World Health Organization lists as a critical-priority pathogen because so few drugs still work against it. ## How it works — jamming the bacterium's LPS conveyor belt Gram-negative bacteria like A. baumannii survive because of a tough outer membrane built from lipopolysaccharide (LPS). Building that membrane depends on a molecular machine called the LptB2FGC complex, which acts like a conveyor belt moving LPS from the inner membrane outward. Zosurabalpin binds and traps that transporter. With the conveyor belt jammed, toxic LPS piles up inside the cell, the outer membrane fails to assemble, and the bacterium dies. Crucially, this target is unrelated to anything existing antibiotics attack — so the resistance mechanisms that defeat carbapenems and most other drugs simply do not apply. The mechanism was detailed in two back-to-back papers published in Nature in January 2024 by scientists at Roche and Harvard. ## Why carbapenem-resistant Acinetobacter is such a problem CRAB causes life-threatening hospital-acquired and ventilator-associated pneumonia and bloodstream infections, often in intensive-care patients who are already critically ill. It resists nearly every class of antibiotic, leaving clinicians to fall back on older, more toxic drugs or combinations of last resort. That is exactly why the WHO flags it as a top-tier priority for new drug development — and why a first-in-class agent that the bug has never seen before is such a big deal. ## The evidence so far In the laboratory, zosurabalpin was potent against a wide panel of human clinical CRAB isolates and cleared lung and thigh infections in mice caused by pan-drug-resistant A. baumannii — and its activity was not blunted by pre-existing resistance mechanisms. Phase 1 studies in healthy volunteers characterized its safety, tolerability and pharmacokinetics and supported moving forward. The honest caveat: it has not yet been proven to cure infections in patients. That is the question the next stage is built to answer. ## The 2026 news — moving into Phase 3 In 2025-2026 Roche advanced zosurabalpin into a global Phase 3 program, enrolling on the order of 400 hospitalized patients with serious CRAB infections and comparing it against standard-of-care antibiotics at sites across Europe, the Americas and Asia. A pivotal trial is the moment of truth for any antibiotic: it determines whether striking preclinical and Phase 1 results translate into real cures with an acceptable safety profile. Because so few new antibiotics reach this stage — and almost none with a brand-new mechanism — zosurabalpin's Phase 3 is one of the most closely watched events in anti-infective drug development. ## Why it matters in 2026 Zosurabalpin is a reminder that peptide chemistry reaches far beyond weight loss and recovery. Tethered macrocyclic peptides give chemists a way to hit difficult bacterial targets that small molecules struggle to reach, and a narrow-spectrum, pathogen-specific design aims to kill the intended bug while sparing the broader microbiome. If the Phase 3 trial succeeds, zosurabalpin would be one of the first truly novel-class antibiotics in a generation and a template for the next wave of drugs against resistant Gram-negative infections. Two honest reminders: it is an unapproved, intravenous, hospital-administered drug available only through controlled clinical trials, and any 'research' source claiming to sell it is not legitimate. Ready to track your peptide research? [Open PepTracker Pro](https://app.peptrackerpro.com) PepTracker Pro Research Team The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges. ## Citations 1. \[1\] Roche to launch phase 3 trial for new antibiotic targeting Acinetobacter baumannii — CIDRAP [Source](https://www.cidrap.umn.edu/antimicrobial-stewardship/roche-launch-phase-3-trial-new-antibiotic-targeting-acinetobacter) 2. \[2\] A novel antibiotic class targeting the lipopolysaccharide transporter — Nature 2024 (PMC) [Source](https://pmc.ncbi.nlm.nih.gov/articles/PMC10794144/) 3. \[3\] Zosurabalpin: a novel tethered macrocyclic peptide antibiotic that kills CRAB — review (PMC) [Source](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11317178/) 4. \[4\] Safety, Tolerability and PK of single-dose zosurabalpin in healthy participants — Phase 1 (PMC) [Source](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678405/) **Disclaimer:** This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. [Read full research disclaimer →](/research-disclaimer) ## Related Articles [![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/aleniglipron-oral-glp1-retatrutide-triumph1-pemvidutide-lancet-ai-antimicrobial-peptides-may-2026) News & Updates [ ### Aleniglipron Joins the Oral GLP-1 Race, Retatrutide TRIUMPH-1 Readout Imminent, Pemvidutide Lancet Publication, and AI-Designed Antimicrobial Peptides Enter Early Trials — May 7, 2026 Peptide Research Update ](/blog/aleniglipron-oral-glp1-retatrutide-triumph1-pemvidutide-lancet-ai-antimicrobial-peptides-may-2026) Structure Therapeutics' aleniglipron posts up to 15.3% weight loss in Phase 2, readying Phase 3 to compete with Foundayo. Retatrutide's pivotal TRIUMPH-1 obesity readout is expected any day. Pemvidutide's MASH data reaches The Lancet with Breakthrough Therapy Designation. And AI-designed antimicrobial peptides advance toward clinics. PepTracker Pro Team May 7, 2026 7 min read aleniglipronGSBR-1290oral-GLP-1 [Read](/blog/aleniglipron-oral-glp1-retatrutide-triumph1-pemvidutide-lancet-ai-antimicrobial-peptides-may-2026) [![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/vk2735-oral-eco-2026-retatrutide-triumph-1-ai-antimicrobial-peptides-oral-wegovy-uptake-pdc-cancer-may-2026) News & Updates [ ### VK2735 Oral Achieves 12.2% Weight Loss at ECO 2026 With Maintenance Data, Retatrutide TRIUMPH-1 Pivotal Readout Imminent With 30%+ Projections, AI Antimicrobial Peptides Hit 79% Success Rate, Oral Wegovy Shows Rapid Real-World Uptake, and Peptide-Drug Conjugates Advance Cancer Precision Delivery — May 18, 2026 Peptide Research Update ](/blog/vk2735-oral-eco-2026-retatrutide-triumph-1-ai-antimicrobial-peptides-oral-wegovy-uptake-pdc-cancer-may-2026) Viking's oral VK2735 achieves 12.2% weight loss at 13 weeks with novel maintenance data at ECO 2026. Retatrutide TRIUMPH-1 pivotal readout due Q2–Q3 2026 with analyst projections above 30%. AI-discovered antimicrobial peptides deliver 79% hit rate from 863K candidate sequences. Oral Wegovy sees rapid real-world adoption with 36% new-to-GLP-1 patients. Peptide-drug conjugates achieve 85% tumor-specific delivery in Phase II. PepTracker Pro Team May 18, 2026 10 min read VK2735Viking-TherapeuticsVENTURE-Oral [Read](/blog/vk2735-oral-eco-2026-retatrutide-triumph-1-ai-antimicrobial-peptides-oral-wegovy-uptake-pdc-cancer-may-2026) [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/zilucoplan-zilbrysq-macrocyclic-peptide-complement-c5-myasthenia-gravis-june-23-2026) Research & Compounds [ ### Zilucoplan (Zilbrysq): The Self-Injectable Peptide That Blocks Complement in Myasthenia Gravis (June 23, 2026) ](/blog/zilucoplan-zilbrysq-macrocyclic-peptide-complement-c5-myasthenia-gravis-june-23-2026) Zilucoplan is a macrocyclic peptide that switches off the final step of the complement cascade. Unlike the IV antibodies that came before it, patients inject it under the skin once a day. Here is how it works and what the evidence shows. PepTracker Pro Team June 23, 2026 9 min read zilucoplanZilbrysqRA101495 [Read](/blog/zilucoplan-zilbrysq-macrocyclic-peptide-complement-c5-myasthenia-gravis-june-23-2026) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.